Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Capecitabine

FDA-approved product (tablet, oral), marketed as Capecitabine, Xeloda.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Capecitabine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Actinic keratosis
  • Adenocarcinoma
  • Basal cell carcinoma
  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Colon carcinoma
  • Colonic neoplasm
  • Colorectal adenocarcinoma
  • Colorectal cancer
  • Colorectal carcinoma
  • Colorectal neoplasm
  • Gastric adenocarcinoma
  • Gastric cancer
  • Gastric carcinoma
  • and 6 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Pyrimidine analogues
FDA pharmacologic class
Nucleoside Metabolic Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli34.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Capecitabine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Capecitabine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)

    NCT07648914 · start 2026-07-06

    Registered record
    Registry ID
    NCT07648914
    Conditions
    Breast Cancer
    Interventions
    BL-B01D1; Albumin-Bound Paclitaxel; Paclitaxel; Capecitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-07-06
    Completion
    2028-12
    Enrolment
    446

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionBL-B01D1; Albumin-Bound Paclitaxel; Paclitaxel; Capecitabine
    PhasePhase 3
    Registry statusRecruiting

  • Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases

    NCT07677293 · start 2026-06-26

    Registered record
    Registry ID
    NCT07677293
    Conditions
    Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
    Interventions
    Retlirafusp alfa Injection; Capecitabine; Oxaliplatin; Sintilimab or Tislelizumab (based on investigator's choice); Capecitabine; Oxaliplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-06-26
    Completion
    2028-12-31
    Enrolment
    332

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
    InterventionRetlirafusp alfa Injection; Capecitabine; Oxaliplatin; Sintilimab or Tislelizumab (based on investigator's choice) +2 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • Total Neoadjuvant Therapy With Additional Consolidation Chemotherapy Followed by Local Excision Versus Total Neoadjuvant Therapy Followed by Local Excision at Stage I Rectal Cancer

    NCT07563907 · start 2026-06-01

    Registered record
    Registry ID
    NCT07563907
    Conditions
    Organ Preservation; Rectal Cancer Stage I; Total Neoadjuvant Treatment; Consolidation Therapy; Capecitabine
    Interventions
    TNT with additional consolidation chemotherapy followed by local excision; TNT followed by local excision
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-06-01
    Completion
    2035-12-31
    Enrolment
    292

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOrgan Preservation; Rectal Cancer Stage I; Total Neoadjuvant Treatment; Consolidation Therapy +1 more
    InterventionTNT with additional consolidation chemotherapy followed by local excision; TNT followed by local excision
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations

    NCT07628504 · start 2026-05-18

    Registered record
    Registry ID
    NCT07628504
    Conditions
    Adjuvant Drug Therapy
    Interventions
    Sacituzumab Tirumotecan (sac-TMT); Capecitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-05-18
    Completion
    2035-03-30
    Enrolment
    420

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdjuvant Drug Therapy
    InterventionSacituzumab Tirumotecan (sac-TMT); Capecitabine
    PhasePhase 3
    Registry statusNot yet recruiting

  • Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

    NCT06346197 · start 2025-12-08

    Registered record
    Registry ID
    NCT06346197
    Conditions
    Gastric Cancer; MSI-H; Metastatic Cancer; Advanced Cancer
    Interventions
    Balstilimab; Botensilimab; Folfox Protocol; XELOX; Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-12-08
    Completion
    2028-05-15
    Enrolment
    132

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Cancer; MSI-H; Metastatic Cancer; Advanced Cancer
    InterventionBalstilimab; Botensilimab; Folfox Protocol; XELOX +1 more
    PhasePhase 3
    Registry statusRecruiting

  • SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC

    NCT07474103 · start 2025-11-30

    Registered record
    Registry ID
    NCT07474103
    Conditions
    Rectal Cancer, Adenocarcinoma
    Interventions
    SCRT; Liposomal Irinotecan; Oxaliplatin; Capecitabine; Sintilimab
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-11-30
    Completion
    2028-12-31
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRectal Cancer, Adenocarcinoma
    InterventionSCRT; Liposomal Irinotecan; Oxaliplatin; Capecitabine +1 more
    PhaseNot applicable
    Registry statusRecruiting

  • STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

    NCT07213570 · start 2025-10-16

    Registered record
    Registry ID
    NCT07213570
    Conditions
    Colorectal Cancer Metastatic
    Interventions
    standard second line treatment, at discretion of the investigator; Regorafenib (BAY73-4506)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-10-16
    Completion
    2027-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer Metastatic
    Interventionstandard second line treatment, at discretion of the investigator; Regorafenib (BAY73-4506)
    PhasePhase 2
    Registry statusRecruiting

  • Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）

    NCT06949111 · start 2025-05-15

    Registered record
    Registry ID
    NCT06949111
    Conditions
    Colon Cancer
    Interventions
    radiotherapy; CAPOX; Capecitabine; Iparomlimab and Tuvonralimab Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-05-15
    Completion
    2030-03
    Enrolment
    128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColon Cancer
    Interventionradiotherapy; CAPOX; Capecitabine; Iparomlimab and Tuvonralimab Injection
    PhasePhase 2
    Registry statusRecruiting

  • IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer

    NCT07692750 · start 2025-04-30

    Registered record
    Registry ID
    NCT07692750
    Conditions
    Advanced Pancreatic Cancer
    Interventions
    IBI343+ capecitabine; IBI343+Capecitabine+oxaliplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2025-04-30
    Completion
    2027-12-31
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Pancreatic Cancer
    InterventionIBI343+ capecitabine; IBI343+Capecitabine+oxaliplatin
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients

    NCT07114627 · start 2025-02-18

    Registered record
    Registry ID
    NCT07114627
    Conditions
    Solid Cancer; Gastric (Cardia, Body) Cancer; Esophageal Cancer; Colorectal Cancer (CRC)
    Interventions
    Blood sampling for pharmacokinetics
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-02-18
    Completion
    2027-06
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Cancer; Gastric (Cardia, Body) Cancer; Esophageal Cancer; Colorectal Cancer (CRC)
    InterventionBlood sampling for pharmacokinetics
    PhaseNot recorded
    Registry statusRecruiting

  • Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer

    NCT06751394 · start 2025-01-01

    Registered record
    Registry ID
    NCT06751394
    Conditions
    Recurrent Rectal Cancer
    Interventions
    PD-1 antibody (Toripalimab); Capecitabine; Oxaliplatin; Irinotecan; Radiation; surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-01-01
    Completion
    2028-12-31
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Rectal Cancer
    InterventionPD-1 antibody (Toripalimab); Capecitabine; Oxaliplatin; Irinotecan +2 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer

    NCT06748508 · start 2024-12-25

    Registered record
    Registry ID
    NCT06748508
    Conditions
    Gastric (Stomach) Cancer
    Interventions
    Sintilimab, oxalipaltin, 5FU,Nab-paclitaxel,lenvatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2024-12-25
    Completion
    2027-12-25
    Enrolment
    141

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric (Stomach) Cancer
    InterventionSintilimab, oxalipaltin, 5FU,Nab-paclitaxel,lenvatinib
    PhasePhase 2
    Registry statusNot yet recruiting

  • Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

    NCT07371910 · start 2024-06-12

    Registered record
    Registry ID
    NCT07371910
    Conditions
    Metastatic Breast Cancer; HRD-Positive/HER2-Negative Advanced Breast Cancer
    Interventions
    Chemotherapy/ADC Regimen; Fluorizoparib; Apatinib; Physician's Choice Chemotherapy/ADC Regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2024-06-12
    Completion
    2031-03
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer; HRD-Positive/HER2-Negative Advanced Breast Cancer
    InterventionChemotherapy/ADC Regimen; Fluorizoparib; Apatinib; Physician's Choice Chemotherapy/ADC Regimen
    PhasePhase 3
    Registry statusActive not recruiting

  • Preoperative Radiotherapy And ASTX660 in Rectum Cancer

    NCT05912075 · start 2023-12-19

    Registered record
    Registry ID
    NCT05912075
    Conditions
    Locally-advanced Rectal Cancer
    Interventions
    mFOLFIRINOX; Pelvic radiotherapy LCRT; Capecitabine; TOLINAPANT (ASTX660); Pelvic radiotherapy SCRT; FOLFOX4; CAPOX
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2023-12-19
    Completion
    2029-01
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally-advanced Rectal Cancer
    InterventionmFOLFIRINOX; Pelvic radiotherapy LCRT; Capecitabine; TOLINAPANT (ASTX660) +3 more
    PhasePhase 1
    Registry statusRecruiting

  • Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy

    NCT06099951 · start 2023-11-01

    Registered record
    Registry ID
    NCT06099951
    Conditions
    Colorectal Cancer
    Interventions
    Serplulimab + FOLFOXIRI; Radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2023-11-01
    Completion
    2027-09-01
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionSerplulimab + FOLFOXIRI; Radiation therapy
    PhasePhase 2
    Registry statusNot yet recruiting